This trial is evaluating whether Durvalumab will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of Up to 30 days following end of treatment.
This trial requires 27 total participants across 2 different treatment groups
This trial involves 2 different treatments. Durvalumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
The main cause of carcinoma of the lung is smoking. However, other factors can also enhance [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) risk, for example air pollution, which is the second most common cause of death from cancer. Smoking causes a number of mutations in the lung epithelium. The carcinogenic process is complex.
Recent findings reveals that, in this population of patients with carcinoma, non-small-cell lung (NSCLC), the preferred treatment strategy is surgery for early-stage (I-IIIA) NSCLC followed by adjuvant platinum-based chemotherapy and/or taxane-containing chemotherapy, although in recent years platinum-containing chemotherapy has shown to be only equivalent to taxane chemotherapy as the second-line treatment for early-stage, locally advanced NSCLC. Radiation therapy following surgery is not indicated, as the evidence was inconclusive.
Carcinoma, non-small cell lung is a common disease. More than 1.1 million U.S. cancer deaths are due to lung malignancy annually. This may be due to the fact that the overall longevity of people in the United States is declining.
Results from a recent clinical trial, there was no interaction between the genotype of the RAS oncogene codon 12 SNP and NQO1 SNP with the clinical characteristics of lung cancer, such as histological type, tumor size and TNM stage when assessing the gene polymorphism in the patients' DNA sequences. Furthermore, the results indicated that the patients with the homozygous genotype GG of the NQO1 SNP of the C/T polymorphism of exon 2-5 could be treated by the lung carcinoma (with low-stage), and therefore, the patients with the C/C genotype were not suitable candidates for lung cancer treatment.
TNF-alpha mediated cytokine signaling is important for tumor cell proliferation and survival in a process that is dependent on tumor cell type. Thus, targeting the NF-kappaB pathway can lead to clinical remission of carcinoma, non-small-cell lung in some patients. It deserves further study as a potential therapeutic target.
Symptoms of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) should be investigated, especially if they mimic asthma, or if they include: breathlessness, coughing and hemoptysis. A chest X-ray is required in patients presenting with complaints of cancer or in those with previous or family history of cancer.
In addition to well established risk factors for [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), the presence of a family history of cancer increased the risk to about 30 times. When an individual from a high-risk family or has a family history, follow-up with lung cancer genetic testing should be conducted.
There are many reasons to trial for lung cancer; even if you fit into any one category, there's still something to work on. Consideration is being given to all patients irrespective of their characteristics. If you are an NSCLC patient and a clinical trial is going to occur, there's still something to work on. To make yourself a part of this clinical trial, visit Power (power).
Durvalumab is a humanized monoclonal antibody that targets the programmed death receptor 1 (PD-1). One study found that those who were treated with durvalumab for metastatic or recurrent non-small cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) were 35% more likely to have a response than those receiving conventional therapy. Durvalumab is approved for cancer treatment by the FDA only when used in combination with PD-1 inhibitors. These drugs consist of nivolumab, pembrolizumab, and pomalidomide. For any given cancer, PD-1 inhibitors are thought to activate the immune system to help cure all cancer patients.
Given the current market situation for anticancer drugs, many patients and their physicians were anxious about the development of new agents. Durvalumab appears to be one of the most attractive agents.
The chances of developing carcinoma and [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) in the future are much lower than those of a person who did not survive cancer or lung cancer. This means that [survivors of cancer or lung cancer should monitor their health carefully as they age, because they are at higher risk of lung cancer and can develop it more easily than their non-survivor friends and family members (http://www.healthspan.com/healthy_lifestyle/lung_cancer/lung_cancer.htm)].
The 5-year survival and 10-year survival rates in our study population with carcinoma, non-small-cell lung were 53.6% and 23.3%, respectively. Survivors with cancer, non-small-cell lung have better survival than non-survivors with the disease. A lower survival rate is associated with older (over 55 years) age.